- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Vical Inc (VICL)
| Open: | 3.6000 | Day's Range: | 3.6000 - 3.7000 | Volume: | 395,272 |
|---|---|---|---|---|---|
| Previous Close: | 3.6100 | 52wk Range: | 2.6100 - 4.7400 | 1-Yr Rtn: | +27.82% |
Key Statistics for VICL
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.3800 |
| Est. EPS (USD) (12/2013) | -0.4570 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 313.81 |
| Shares Outstanding (M) | 86.45 |
| 30 Day Average Volume | 661,640 |
| Price/Book (mrq) | 3.8607 |
| Price/Sale (ttm) | 41.1168 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for VICL
Company Profile & Key Executives for VICL
Vical Incorporated develops gene-based pharmaceutical products for human therapy. The Company develops cancer product candidates, as well as develops vaccines for infectious diseases and gene-based delivery of therapeutic proteins for other disorders.
| Vijay B SamantPresident/CEO/Acting CFO | Anthony A RamosChief Accounting Officer |
| Alain P RollandExec VP:Product Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
VICL News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page